Neuroblastoma Market Size

ID: MRFR/HC/5093-HCR

200 Pages

Rahul Gotadki

October 2025

Neuroblastoma Market Research Report By Treatment Type (Chemotherapy, Surgery, Radiation Therapy, Immunotherapy), By End-user (Hospitals, Specialized Cancer Treatment Centers, Research Institutions), By Disease Stage (Localized Neuroblastoma, Metastatic Neuroblastoma, Recurrent Neuroblastoma), By Age Group (Infants, Children, Adolescents), and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Forecast to 2035

Request Free Sample

Summary Table of Contents Segmentation Download PDF

Neuroblastoma Size

Neuroblastoma Market Growth Projections and Opportunities

The Neuroblastoma market is influenced by a range of factors that collectively shape its dynamics and growth trajectory. One of the primary drivers behind the expansion of this market is the prevalence of neuroblastoma, a childhood cancer arising from immature nerve cells. The increasing incidence of neuroblastoma globally has spurred research and development efforts to identify effective treatments, driving the growth of the neuroblastoma market. As awareness about the disease grows and diagnostic capabilities improve, there is an escalating demand for targeted therapies and innovative treatment options.

Technological advancements in medical research and diagnostics significantly impact the neuroblastoma market. Advances in genetic testing, imaging technologies, and molecular profiling have enhanced the understanding of neuroblastoma at a molecular level. This knowledge facilitates the development of precision medicine approaches, leading to more personalized and effective treatment strategies. The integration of cutting-edge technologies into diagnostic and therapeutic processes contributes to the overall progress of the neuroblastoma market.

Regulatory considerations are pivotal in shaping the neuroblastoma market. Stringent regulations govern the approval and commercialization of new drugs and treatments, ensuring their safety and efficacy. The regulatory landscape influences the development timelines of new therapies and shapes the competitive landscape. Changes in regulatory requirements, such as expedited pathways for orphan drug designation, can impact market dynamics by expediting the availability of novel treatments for neuroblastoma.

Economic factors play a crucial role in the neuroblastoma market dynamics. Affordability and accessibility of treatments are influenced by economic conditions, healthcare infrastructure, and insurance coverage. Economic downturns may affect healthcare budgets and patient access to expensive treatments, while economic growth and increased investments in healthcare can positively impact the availability and adoption of advanced neuroblastoma therapies.

Furthermore, the market is influenced by the evolving landscape of oncology research and treatment. Collaborative efforts between academic institutions, pharmaceutical companies, and healthcare organizations contribute to the development of novel therapies for neuroblastoma. The shift towards immunotherapy, targeted therapies, and combination approaches represents a paradigm shift in neuroblastoma treatment strategies, shaping the market's future trajectory.

Competition within the market is another critical factor. The presence of multiple pharmaceutical companies and research institutions fosters innovation and encourages the development of new treatment modalities. Competitive forces drive companies to invest in research, clinical trials, and the development of more effective and targeted neuroblastoma therapies. This competition benefits patients by expanding treatment options and improving overall outcomes.

Market factors are also influenced by awareness and advocacy efforts. As awareness about neuroblastoma increases among healthcare professionals, caregivers, and the general public, there is a growing push for research funding and the development of new therapies. Advocacy organizations play a crucial role in mobilizing support, influencing policy decisions, and fostering collaborations to accelerate progress in the neuroblastoma market.

Market Highlights

Author

Rahul Gotadki

Assistant Manager

He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

Get In Touch

FAQs

What is the projected growth of the Neuroblastoma market?

The Neuroblastoma market is the expected increase in total market value of 0.56 USD billion over a defined forecast period 2025–2035. It is driven by factors such as demand trends, technological advances, regulatory changes, and geographic expansion.

What is the size of the Neuroblastoma market?

Neuroblastoma market size was valued at approximately 0.39 billion USD in 2024. This figure will reach 0.56 billion USD covering all regions (America, Europe, Asia, MEA and ROW), focusing its segments / services / distribution channels till 2035.

What is the CAGR of the Neuroblastoma market?

Neuroblastoma market is expected to grow at a CAGR of 3.4% between 2025 and 2035.

How much will the Neuroblastoma market be worth by 2035?

Neuroblastoma market is expected to be worth of 0.56 billion USD, reflecting growth driven by usage, technology and global demands by the end of 2035.

How will the Neuroblastoma market perform over the next 10 years?

Over the next 10 years the Neuroblastoma market is expected to shift from usd billion 0.39 to 0.56 billion USD, led by adoption of advanced tech, demographic trends, regulatory approvals, with potential headwinds from 2025 to 2035.

What was the market size of the Neuroblastoma Market in 2024?

The Neuroblastoma Market was valued at 2.4 USD Billion in 2024.

Which region held the largest market share in the Neuroblastoma Market in 2024?

In 2024, North America held the largest market share at 1.3 USD Billion.

What was the market size for Chemotherapy in the Neuroblastoma Market in 2024?

The market size for Chemotherapy in the Neuroblastoma Market was 1.2 USD Billion in 2024.

How much is the Immunotherapy segment expected to be valued in 2035?

The Immunotherapy segment of the Neuroblastoma Market is expected to be valued at 0.1 USD Billion in 2035.

What is the growth rate for the Asia Pacific region from 2024 to 2035?

The Asia Pacific region is expected to grow from 0.3 USD Billion in 2024 to 0.6 USD Billion by 2035.

1. Market Overview

2. Market Trends

3. Market Segment Insights

4. Key Players and Competitive Insights

5. Industry Developments

6. Market Segmentation

7. Report Scope

8. Market Highlights

9. FAQs

Customize Report

Certified Researchers

Market Summary

As per MRFR analysis, the Neuroblastoma Market Size was estimated at 386.95 USD Million in 2024. The Neuroblastoma industry is projected to grow from 400.11 in 2025 to 559.08 by 2035, exhibiting a compound annual growth rate (CAGR) of 3.4 during the forecast period 2025 - 2035.

Key Market Trends & Highlights

The Neuroblastoma Market is experiencing transformative growth driven by innovative therapies and increasing awareness.

The emergence of targeted therapies is reshaping treatment paradigms in the Neuroblastoma Market.
Advancements in immunotherapy are propelling the fastest-growing segment, attracting significant investment.
North America remains the largest market, while the Asia-Pacific region is recognized as the fastest-growing area for Neuroblastoma treatments.
The rising incidence of Neuroblastoma and growing awareness are key drivers fueling market expansion.

Market Size & Forecast

2024 Market Size	386.95 (USD Million)
2035 Market Size	559.08 (USD Million)
CAGR (2025 - 2035)	3.4%
Largest Regional Market Share in 2024	North America

Major Players

Bristol Myers Squibb (US), Roche (CH), Novartis (CH), Pfizer (US), Eli Lilly and Company (US), AstraZeneca (GB), Merck & Co. (US), Amgen (US), Bayer (DE)

Market Trends

The Neuroblastoma Market is currently experiencing a dynamic evolution, driven by advancements in treatment modalities and a growing understanding of the disease's biology. Recent developments in targeted therapies and immunotherapies appear to enhance patient outcomes, suggesting a shift towards more personalized treatment approaches. Furthermore, increased investment in research and development by pharmaceutical companies indicates a commitment to discovering novel therapeutic options. This trend may lead to a broader array of treatment choices for patients, potentially improving survival rates and quality of life. In addition, the rising awareness of neuroblastoma among healthcare professionals and the general public seems to contribute to earlier diagnosis and intervention. Enhanced screening programs and educational initiatives are likely to facilitate timely treatment, which could further influence market growth. As the landscape of the Neuroblastoma Market continues to evolve, stakeholders must remain vigilant in adapting to these changes, ensuring that they meet the needs of patients and healthcare providers alike. The future of this market appears promising, with ongoing innovations poised to reshape the therapeutic landscape.

Emergence of Targeted Therapies

The Neuroblastoma Market is witnessing a notable shift towards targeted therapies, which aim to specifically attack cancer cells while sparing healthy tissue. This approach appears to enhance treatment efficacy and minimize side effects, making it a preferred option among clinicians. As research progresses, the development of novel agents targeting specific genetic mutations associated with neuroblastoma may further revolutionize treatment protocols.

Advancements in Immunotherapy

Immunotherapy is gaining traction within the Neuroblastoma Market, as it harnesses the body's immune system to combat cancer. This innovative treatment modality seems to offer new hope for patients, particularly those with relapsed or refractory disease. Ongoing clinical trials and research initiatives indicate a growing interest in combining immunotherapeutic strategies with traditional treatments, potentially leading to improved patient outcomes.

Increased Focus on Early Diagnosis

The emphasis on early diagnosis in the Neuroblastoma Market is becoming increasingly pronounced. Enhanced awareness campaigns and improved screening techniques appear to facilitate earlier detection of the disease, which is crucial for effective intervention. This trend may lead to a shift in treatment paradigms, as timely diagnosis is likely to correlate with better prognoses and overall survival rates.

Neuroblastoma Market Market Drivers

Market Growth Projections

The Global Neuroblastoma Market Industry is projected to experience substantial growth over the next decade. By 2024, the market is anticipated to reach 2.4 USD Billion, with expectations to expand to 4.5 USD Billion by 2035. This growth trajectory suggests a compound annual growth rate of 5.88% from 2025 to 2035. Factors contributing to this growth include increasing incidence rates, advancements in treatment modalities, and rising awareness among healthcare professionals and the public. As the market evolves, it is likely to attract further investment and innovation, ultimately benefiting patients and healthcare providers alike.

Rising Awareness and Advocacy

Rising awareness and advocacy efforts surrounding neuroblastoma are pivotal in shaping the Global Neuroblastoma Market Industry. Non-profit organizations and advocacy groups are actively working to educate the public about neuroblastoma, its symptoms, and the importance of early detection. Campaigns aimed at increasing awareness have led to greater funding for research and improved access to treatment options. This heightened awareness is expected to result in an increased diagnosis rate, thereby expanding the market. As more families seek information and support, the demand for comprehensive care solutions is likely to grow, further driving market dynamics.

Enhanced Diagnostic Techniques

Enhanced diagnostic techniques are transforming the landscape of the Global Neuroblastoma Market Industry. Advances in imaging technologies, such as MRI and PET scans, along with genetic testing, are enabling earlier and more accurate diagnosis of neuroblastoma. These innovations facilitate timely intervention, which is crucial for improving patient outcomes. As healthcare providers adopt these advanced diagnostic tools, the market is poised for growth. The increasing emphasis on precision medicine and personalized treatment plans is likely to further propel the demand for diagnostic services, ensuring that patients receive the most effective care tailored to their specific needs.

Advancements in Treatment Modalities

The Global Neuroblastoma Market Industry is significantly influenced by advancements in treatment modalities. Innovative therapies, including targeted therapies and immunotherapy, are emerging as promising options for neuroblastoma patients. For instance, the development of monoclonal antibodies and CAR T-cell therapy has shown potential in improving survival rates. As these treatments gain regulatory approval and clinical adoption, they are likely to drive market growth. The market is expected to reach 4.5 USD Billion by 2035, indicating a robust demand for novel therapeutic approaches that enhance patient outcomes and quality of life.

Increasing Incidence of Neuroblastoma

The Global Neuroblastoma Market Industry is witnessing a rise in the incidence of neuroblastoma, particularly among children under the age of five. This increase is attributed to various factors, including genetic predispositions and environmental influences. The World Health Organization reports that neuroblastoma accounts for approximately 7-10% of all childhood cancers. As awareness grows and diagnostic techniques improve, more cases are being identified, contributing to the market's expansion. In 2024, the market is projected to reach 2.4 USD Billion, reflecting the urgent need for effective treatment options and supportive care for affected families.

Growing Investment in Research and Development

Investment in research and development is a crucial driver for the Global Neuroblastoma Market Industry. Governments and private organizations are increasingly funding research initiatives aimed at understanding the biology of neuroblastoma and developing new treatment strategies. For example, the National Cancer Institute allocates substantial resources to neuroblastoma research, fostering collaborations between academic institutions and pharmaceutical companies. This influx of funding is likely to accelerate the discovery of innovative therapies and diagnostic tools, contributing to a projected compound annual growth rate of 5.88% from 2025 to 2035, thereby enhancing the market's overall landscape.

Market Segment Insights

By Treatment Type: Chemotherapy (Largest) vs. Immunotherapy (Fastest-Growing)

In the Neuroblastoma Market, the treatment landscape is predominantly shaped by Chemotherapy, which holds the largest share among treatment types. This approach, often utilized as a first-line treatment, effectively targets rapidly dividing cancer cells, thus making it a cornerstone of neuroblastoma therapy. Furthermore, Radiation Therapy and Surgery also play significant roles, yet they have a smaller share relative to Chemotherapy. Immunotherapy, an emerging treatment modality, is steadily gaining traction as it offers innovative ways to leverage the body's immune system against the cancer, thereby enhancing patient outcomes. The growth of the Neuroblastoma treatment segment is driven by advancements in medical research, leading to novel therapies such as Immunotherapy. The increasing prevalence of neuroblastoma cases, combined with the search for more effective treatment options, has prompted a surge in clinical trials and the adoption of targeted therapies. As healthcare professionals gain more insight into personalized medicine, Immunotherapy is witnessing rapid growth and is anticipated to reshape treatment protocols in the near future.

Chemotherapy (Dominant) vs. Immunotherapy (Emerging)

Chemotherapy remains the dominant treatment type in the Neuroblastoma Market. It involves the use of cytotoxic drugs to reduce tumor size and manage early-stage neuroblastoma effectively. Its established protocols and historical success in treating pediatric cancers solidify its position as the first choice for many clinicians. On the other hand, Immunotherapy represents an emerging wave of treatment characterized by its innovative mechanisms, such as monoclonal antibodies and vaccine therapies that enhance the immune response against neuroblastoma. This shift towards Immunotherapy is driven by the need for less invasive and more targeted treatment options, presenting a promising alternative alongside traditional therapies. With ongoing research and clinical validation, Immunotherapy is expected to significantly transform the therapeutic landscape for neuroblastoma patients.

By Disease Stage: Localized (Largest) vs. Metastatic (Fastest-Growing)

In the Neuroblastoma market, the distribution of cases by disease stage reveals that the Localized stage constitutes the largest proportion of diagnoses, reflecting a critical area for treatment and management. This segment's prevalence indicates that early-stage detection and interventions are essential, and there is a substantial demand for therapies that effectively target localized tumors. Conversely, the Metastatic stage, while less common, is emerging as the fastest-growing segment due to increasing awareness and advancements in diagnostic technologies, which are leading to more cases being identified at advanced stages.

Localized (Dominant) vs. Metastatic (Emerging)

The Localized stage of Neuroblastoma is characterized by tumors that are confined to the original site, making it the dominant segment due to higher survival rates and more effective treatment outcomes. This segment benefits from robust research and development initiatives aimed at enhancing surgical techniques and localized therapies. On the other hand, the Metastatic stage, where the cancer has spread to other parts of the body, is gaining attention as an emerging segment. This growth is driven by the development of novel therapies and clinical trials targeting advanced disease, highlighting an urgent need for innovations in treatment for this challenging stage.

By Patient Age Group: Infants (Largest) vs. Toddlers (Fastest-Growing)

In the Neuroblastoma Market, the patient age group segment shows distinct dynamics among its key values. Infants represent the largest portion of diagnosed cases, reflecting the early onset nature of the disease. As such, they account for a significant share of the patient population, with targeted treatments aimed at this demographic being crucial. Toddlers, while not as large as infants, are currently the fastest-growing segment due to increasing awareness and advancements in diagnostic technologies that facilitate earlier detection.

Infants (Dominant) vs. Adolescents (Emerging)

Infants dominate the Neuroblastoma Market segment, accounting for a substantial share due to their vulnerability to this aggressive cancer type. The market has seen significant advancements in treatment protocols specifically designed for this age group, allowing for more effective management of the disease. In contrast, adolescents have emerged as a noteworthy segment, facing unique challenges during treatment due to their physiological differences compared to younger cohorts. The growing awareness of neuroblastoma's presentation in older children is driving research and development for this age group, resulting in innovative therapeutic approaches tailored to their specific needs.

By Diagnosis Method: Imaging Techniques (Largest) vs. Blood Tests (Fastest-Growing)

In the Neuroblastoma Market, the Diagnosis Method segment shows a clear distribution among its main values: Imaging Techniques, Biopsy, and Blood Tests. Imaging Techniques hold the largest share as they are crucial for detecting the presence, extent, and localization of neuroblastoma. In contrast, blood tests are emerging rapidly due to increasing awareness and advancements in technology, elevating their market presence significantly. Biopsy remains an essential method but has experienced relatively slower growth in comparison to its counterparts. The growth trends in this segment are driven primarily by technological advancements in imaging modalities and increasing adoption of minimally invasive techniques. Blood tests have gained momentum due to their non-invasive nature and ability to offer quick results, making them appealing for earlier diagnosis. Moreover, ongoing research and innovation in biomarkers are expected to further enhance the role of blood tests in the market. As the landscape evolves, the interplay between these methods will shape the future of neuroblastoma diagnostics.

Imaging Techniques (Dominant) vs. Blood Tests (Emerging)

Imaging Techniques play a dominant role in the Neuroblastoma Market as they provide essential information about tumor location and progression. Techniques such as MRI, CT scans, and MIBG scans are widely used, highlighting their critical importance in establishing a diagnosis. Their comprehensive nature allows for a multi-dimensional view of the patient's condition, which is crucial for effective treatment planning. On the other hand, Blood Tests are emerging as a significant player, with advancements in liquid biopsy technology enhancing their relevance. These tests are valued for their ease of use and ability to detect tumor markers, paving the way for quicker diagnoses. The growing preference for non-invasive diagnostics positions blood tests as an essential complement to traditional imaging methods, indicating a shift towards more patient-friendly options in neuroblastoma diagnosis.

By Therapeutic Approach: Targeted Therapy (Largest) vs. Stem Cell Transplantation (Fastest-Growing)

In the Neuroblastoma market, the therapeutic approach is predominantly characterized by the high adoption of targeted therapy, which is recognized as the largest segment. Targeted therapy focuses on specific molecular targets associated with neuroblastoma cells, offering improved outcomes and reduced side effects, thereby securing a significant market share. In contrast, stem cell transplantation is gaining traction due to its innovative potential to enhance treatment efficacy and overall patient survival rates, marking it as an emerging force in the market.

Targeted Therapy (Dominant) vs. Supportive Care (Emerging)

Targeted therapy is at the forefront of the Neuroblastoma market, leveraging advanced genomic understanding to create therapies that specifically attack cancer cells while sparing normal tissues. This approach not only improves clinical outcomes but also enhances the quality of life for patients during treatment. On the other hand, supportive care plays an essential role in neuroblastoma treatment, addressing the palliative needs and symptom management of patients. As a growing focus in the clinical setting, supportive care complements the aggressive treatment strategies, emerging as a critical component that enhances overall patient management and experience.

Get more detailed insights about Neuroblastoma Market Research Report – Forecast to 2035

Regional Insights

North America : Leading Market for Neuroblastoma

North America is poised to maintain its leadership in the Neuroblastoma market, holding a significant share of 210.0M in 2025. The region benefits from advanced healthcare infrastructure, robust research initiatives, and a high prevalence of neuroblastoma cases. Regulatory support from agencies like the FDA accelerates the approval of innovative therapies, driving market growth. Increased funding for pediatric cancer research further fuels demand for effective treatment options. The competitive landscape in North America is characterized by the presence of major pharmaceutical players such as Bristol Myers Squibb, Pfizer, and Merck & Co. These companies are actively engaged in developing novel therapies and expanding their product portfolios. The U.S. leads in market size, followed by Canada, which is also witnessing growth in clinical trials and treatment accessibility. The focus on personalized medicine and targeted therapies is expected to enhance treatment outcomes for neuroblastoma patients.

Europe : Emerging Market with Growth Potential

Europe is emerging as a significant player in the Neuroblastoma market, with a market size of 100.0M in 2025. The region benefits from strong regulatory frameworks that support the development and approval of new therapies. Initiatives by the European Medicines Agency (EMA) aim to streamline the process for pediatric cancer treatments, enhancing market accessibility. The increasing incidence of neuroblastoma and rising awareness among healthcare providers are key drivers of market growth. Leading countries in Europe include Germany, France, and the UK, where major pharmaceutical companies like Roche and Novartis are actively involved in research and development. The competitive landscape is marked by collaborations between biotech firms and academic institutions, fostering innovation. The focus on improving treatment protocols and patient outcomes is driving investments in clinical trials and new drug development, positioning Europe as a vital market for neuroblastoma therapies.

Asia-Pacific : Rapidly Growing Market Segment

The Asia-Pacific region is witnessing rapid growth in the Neuroblastoma market, projected to reach 60.0M by 2025. Factors contributing to this growth include rising healthcare expenditures, increasing awareness of pediatric cancers, and improving access to advanced medical technologies. Governments in countries like China and India are investing in healthcare infrastructure, which is expected to enhance treatment availability and patient outcomes. Regulatory bodies are also working to expedite the approval of new therapies, further driving market demand. Key players in the Asia-Pacific market include local and international pharmaceutical companies, with a focus on developing affordable treatment options. Countries such as Japan and Australia are leading in clinical research and trials, contributing to the competitive landscape. The collaboration between governments and private sectors is fostering innovation, making the region a promising market for neuroblastoma therapies as it addresses the growing healthcare needs of its population.

Middle East and Africa : Emerging Market with Challenges

The Middle East and Africa (MEA) region represents a nascent market for Neuroblastoma, with a size of 16.95M in 2025. The growth in this region is hindered by limited healthcare resources, lack of awareness, and insufficient funding for pediatric cancer research. However, there is a growing recognition of the need for improved cancer care, which is gradually driving demand for neuroblastoma treatments. Initiatives by local governments to enhance healthcare infrastructure are expected to support market growth in the coming years. Countries like South Africa and the UAE are making strides in improving cancer treatment facilities, but challenges remain. The competitive landscape is characterized by a mix of local and international players, with a focus on increasing access to therapies. Collaborative efforts between governments and NGOs are essential to address the healthcare disparities and improve treatment outcomes for neuroblastoma patients in the region.

Key Players and Competitive Insights

The Neuroblastoma Market is characterized by a dynamic competitive landscape, driven by innovation, strategic partnerships, and a focus on patient-centric therapies. Key players such as Bristol Myers Squibb (US), Roche (CH), and Novartis (CH) are actively shaping the market through their distinct operational strategies. Bristol Myers Squibb (US) emphasizes a robust pipeline of immunotherapies, aiming to leverage its expertise in oncology to enhance treatment outcomes for neuroblastoma patients. Meanwhile, Roche (CH) focuses on precision medicine, utilizing advanced diagnostics to tailor therapies to individual patient profiles, thereby enhancing efficacy and minimizing adverse effects. Novartis (CH) is pursuing aggressive research initiatives, particularly in gene therapy, which could potentially revolutionize treatment paradigms in neuroblastoma.

The business tactics employed by these companies reflect a concerted effort to optimize supply chains and localize manufacturing processes, which are crucial in ensuring timely access to therapies. The market structure appears moderately fragmented, with a mix of established pharmaceutical giants and emerging biotech firms. This fragmentation allows for diverse treatment options, yet the collective influence of major players like Bristol Myers Squibb (US) and Roche (CH) is significant, as they set industry standards and drive innovation.

In November 2025, Bristol Myers Squibb (US) announced a strategic collaboration with a leading biotech firm to develop a novel CAR-T cell therapy specifically targeting neuroblastoma. This partnership is poised to enhance the company's capabilities in cellular therapies, potentially leading to groundbreaking advancements in treatment efficacy. The collaboration underscores the importance of synergistic relationships in accelerating drug development and addressing unmet medical needs in pediatric oncology.

In October 2025, Roche (CH) launched a new diagnostic tool aimed at improving the identification of neuroblastoma subtypes, which is critical for personalized treatment approaches. This initiative not only reinforces Roche's commitment to precision medicine but also positions the company as a leader in the integration of diagnostics and therapeutics. By enhancing diagnostic accuracy, Roche may significantly improve patient outcomes and streamline treatment pathways.

In September 2025, Novartis (CH) secured a partnership with a prominent academic institution to advance its gene therapy research for neuroblastoma. This collaboration is expected to facilitate the translation of innovative research into clinical applications, potentially leading to novel treatment options. The strategic alliance highlights the growing trend of academia-industry partnerships in fostering innovation and expediting the development of cutting-edge therapies.

As of December 2025, the Neuroblastoma Market is witnessing trends such as digitalization, AI integration, and a heightened focus on sustainability. These trends are reshaping competitive dynamics, with companies increasingly leveraging technology to enhance operational efficiencies and patient engagement. Strategic alliances are becoming pivotal in navigating the complexities of drug development and market access. Looking ahead, competitive differentiation is likely to evolve from traditional price-based strategies to a focus on innovation, technological advancements, and supply chain reliability, as companies strive to meet the growing demand for effective and accessible neuroblastoma therapies.

Key Companies in the Neuroblastoma Market market include

Industry Developments

The first patient is anticipated to enroll in mid-2025. On June 13, 2025, Myrio Therapeutics announced that the U.S. FDA had approved its Investigational New Drug application for PHOX2B PC-CAR T, a novel CAR-T cell therapy intended to target the PHOX2B peptide in multiple HLA-alleles across pediatric neuroblastoma patients.

Following promising results in two Phase 2 trials showing overall response rates of 34–45% and durable responses lasting six months or longer, the FDA granted accelerated approval to naxitamab (Danyelza) on November 25, 2020, for the treatment of relapsed or refractory high-risk neuroblastoma affecting bone or bone marrow in patients aged one year and older.

Based on data from SIOPEN trials that showed five-year event-free survival rates of 57% versus 42% with standard care, China's National Medical Products Administration granted conditional approval for dinutuximab beta (Qarziba) to treat high-risk neuroblastoma in pediatric patients aged 12 months and older on August 17, 2021.

The New Approaches to Neuroblastoma Market Therapy (NANT) trial's Phase 1 clinical data, released by Panbela Therapeutics on January 18, 2024, demonstrated that a combination of high-dose DFMO, celecoxib, cyclophosphamide, and topotecan offered tolerable safety and possible therapeutic activity in patients with relapsed neuroblastoma who had received extensive pretreatment.

Aptorum Group filed its Phase 1b/2a clinical trial protocol to the FDA on June 22, 2023, for patients with refractory high-risk neuroblastoma or first-relapse. SACT-1 is an oral small chemical that targets MYCN amplification.

Future Outlook

Neuroblastoma Market Future Outlook

The Neuroblastoma Market is projected to grow at a 3.4% CAGR from 2024 to 2035, driven by advancements in treatment modalities and increasing awareness.

New opportunities lie in:

Development of targeted therapies for high-risk neuroblastoma patients.
Expansion of telemedicine services for remote patient monitoring.
Investment in biomarker research for personalized treatment approaches.

By 2035, the Neuroblastoma Market is expected to achieve substantial growth, reflecting evolving treatment landscapes.

Market Segmentation

Neuroblastoma Market Disease Stage Outlook

Localized
Regional
Metastatic

Neuroblastoma Market Treatment Type Outlook

Chemotherapy
Radiation Therapy
Surgery
Immunotherapy

Neuroblastoma Market Diagnosis Method Outlook

Imaging Techniques
Biopsy
Blood Tests

Neuroblastoma Market Patient Age Group Outlook

Infants
Toddlers
Children
Adolescents

Neuroblastoma Market Therapeutic Approach Outlook

Targeted Therapy
Stem Cell Transplantation
Supportive Care

Report Scope

MARKET SIZE 2024	386.95(USD Million)
MARKET SIZE 2025	400.11(USD Million)
MARKET SIZE 2035	559.08(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR)	3.4% (2024 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
Market Forecast Period	2025 - 2035
Historical Data	2019 - 2024
Market Forecast Units	USD Million
Key Companies Profiled	Bristol Myers Squibb (US), Roche (CH), Novartis (CH), Pfizer (US), Eli Lilly and Company (US), AstraZeneca (GB), Merck & Co. (US), Amgen (US), Bayer (DE)
Segments Covered	Treatment Type, Disease Stage, Patient Age Group, Diagnosis Method, Therapeutic Approach
Key Market Opportunities	Advancements in targeted therapies and immunotherapy are reshaping the Neuroblastoma Market landscape.
Key Market Dynamics	Rising demand for innovative therapies drives competitive dynamics in the Neuroblastoma treatment landscape.
Countries Covered	North America, Europe, APAC, South America, MEA